Vaxxinity Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VAXX Nasdaq 8731 https://vaxxinity.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vaxxinity Inc

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update - May 9th, 2023 12:00 pm
Vaxxinity, Inc.'s (NASDAQ:VAXX) biggest owners are private companies who got richer after stock soared 23% last week - May 3rd, 2023 10:53 am
Weekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro Recap - Apr 24th, 2023 6:09 am
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April - Mar 28th, 2023 12:00 pm
Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates - Mar 27th, 2023 11:50 am
Vaxxinity Joins TransCelerate Research and Development Consortium - Mar 21st, 2023 12:00 pm
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia - Mar 20th, 2023 12:00 pm
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences - Mar 2nd, 2023 1:00 pm
Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida - Feb 2nd, 2023 12:40 am
Why Shares of Vaxxinity Jumped This Week - Jan 19th, 2023 7:04 pm
Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference - Jan 5th, 2023 1:00 pm
Estimating The Fair Value Of Vaxxinity, Inc. (NASDAQ:VAXX) - Dec 31st, 2022 12:35 pm
Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612 - Dec 2nd, 2022 1:00 pm
Why Shares of Vaxxinity Soared This Week - Dec 2nd, 2022 10:30 am
Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 10th, 2022 12:30 pm
Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022 - Nov 3rd, 2022 12:00 pm
Vaxxinity to Present at Upcoming Investor Conferences in November - Nov 1st, 2022 1:00 pm
Vaxxinity, Inc. (NASDAQ:VAXX) stock most popular amongst private companies who own 48%, while individual investors hold 21% - Oct 30th, 2022 2:27 pm
Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia - Oct 24th, 2022 12:00 pm
Multiple insiders bought Vaxxinity, Inc. (NASDAQ:VAXX) stock earlier this year, a positive sign for shareholders - Sep 19th, 2022 1:00 pm